Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group

被引：41

作者：

Furusyo, Norihiro

Kajiwara, Eiji ^{[9
]}

Takahashi, Kazuhiro ^{[2
]}

Nomura, Hideyuki ^{[10
]}

Tanabe, Yuichi ^{[3
]}

Masumoto, Akihide ^{[11
]}

Maruyama, Toshihiro ^{[12
]}

Nakamuta, Makoto ^{[4
]}

Enjoji, Munechika ^{[5
,6
]}

Azuma, Koichi ^{[7
]}

Shimono, Junya ^{[13
]}

Sakai, Hironori ^{[14
]}

Shimoda, Shinji ^{[8
]}

Hayashi, Jun ^{[1
]}

机构：

[1] Kyushu Univ Hosp, Dept Gen Med, Higashi Ku, Fukuoka 8128582, Japan

[2] Hamanoumachi Hosp, Dept Med, Fukuoka, Japan

[3] Fukuoka City Hosp, Dept Med, Fukuoka, Japan

[4] Natl Hosp Org, Kyushu Med Ctr, Dept Gastroenterol, Fukuoka, Japan

[5] Kyushu Univ, Dept Med, Grad Sch Med Sci, Fukuoka 812, Japan

[6] Kyushu Univ, Dept Bioregulatory Sci, Grad Sch Med Sci, Fukuoka 812, Japan

[7] Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Fukuoka 812, Japan

[8] Kyushu Univ, Dept Med & Biosyst Sci, Grad Sch Med Sci, Fukuoka 812, Japan

[9] Nippon Steel Yawata Mem Hosp, Dept Internal Med, Kitakyushu, Fukuoka, Japan

[10] Shin Kokura Hosp, Ctr Liver Dis, Kitakyushu, Fukuoka, Japan

[11] Natl Hosp Org, Kokura Hosp, Dept Clin Res, Kitakyushu, Fukuoka, Japan

[12] Kitakyushu Municipal Med Ctr, Dept Med, Kitakyushu, Fukuoka, Japan

[13] Yahata Saiseikai Hosp, Dept Med, Kitakyushu, Fukuoka, Japan

[14] Natl Hosp Org Beppu Med Ctr, Dept Gastroenterol, Beppu, Oita, Japan

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2008年 / 23卷 / 07期

关键词：

hepatitis C virus; pegylated interferon alpha-2b; ribavirin;

D O I：

10.1111/j.1440-1746.2008.05319.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim: The aim of the present study was to investigate the association between the length of the treatment period and the cumulative dose of pegylated interferon alpha-2b (peg-IFN alpha-2b) plus ribavirin (RBV) and their effectiveness in the treatment of chronic hepatitis C. Methods: Seven hundred and fifteen patients received peg-IFN alpha-2b plus RBV treatment for 48 weeks and 24 weeks for genotypes 1 (n = 586) and 2 (n = 129), respectively. Results: Sustained virological responses (SVR), defined as serum hepatitis C virus (HCV)-RNA undetectable at 24 weeks after the end of treatment, were 42.4% and 74.4% in genotypes 1 and 2, respectively, on an intention-to-treat analysis. SVR significantly increased with treatment length (4.7%, 36.4%, and 51.8% for < 24 weeks, 24-47 weeks, and 48 weeks, respectively, for genotype 1; and 28.6%, 57.1%, 78.3% for < 12 weeks, 12-23 weeks, and 24 weeks, respectively, for genotype 2). SVR significantly increased with total cumulative treatment dose (21.1%, 36.5%, and 52.9% with < 60%, 60-79%, and >= 80% in peg-IFN dose; 29.6%, 51.1%, and 59.2% with < 60%, 60-79%, and >= 80% in RBV dose) in genotype 1, although it did not differ significantly for genotype 2. Conclusions: In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients.

引用

页码：1094 / 1104

页数：11

共 29 条

[1] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].